AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

BNGO · NASDAQ · Medical - Instruments & Supplies

Bionano Genomics

Optical genome mapping systems, software and consumables for structural-variation analysis.

$1.17

After-hours close0.00 (0.00%)

At close$1.17(−3.31%)

Something off on this page? Send us feedback.

Profile

Bionano Genomics, Inc.BNGOHealth Care

Sells optical genome mapping systems, recurring chips and reagents, analysis software, sample-purification tools and limited laboratory services. The model increasingly depends on utilization of an installed base by research and clinical laboratories, while instrument products are designated for research use only.

Combines optical genome mapping systems—Saphyr and Stratys—with single-use chips, sample-preparation kits and reagents. Labeled, ultra-high-molecular-weight DNA is linearized in nanochannels and imaged to identify large structural variation, a complement to base-by-base sequencing.

Extends the workflow with VIA, Bionano Access, Nexus Copy Number and Compute On Demand for analysis, interpretation and reporting across OGM, sequencing and microarray data. The Ionic system isolates and purifies nucleic acids for OGM and other uses; a San Diego laboratory provides limited OGM testing and data services.

Serves research institutions, clinical laboratories and life-science companies across international markets. Instruments are research-use-only; commercial progress depends on laboratory adoption and use of the installed base, manufacturing partners, evidence, reimbursement pathways for laboratory services and continued regulatory compliance.

Company facts

CEOAlbert A. Luderer, Ph.D.

ListedSep 21, 2018

ExchangeNASDAQ

HeadquartersSan Diego, CA

CountryUnited States

Employees97

CIK0001411690

ISINUS09075F4046

Key statistics

Market cap$13.4M

EPS (ttm)−$3.73

P/E (ttm)−0.3137

ROE-78.8%

P/B0.4274

P/S0.4449

Dividend yield—

Beta1.42vs XLV 0.24

Year to date −26.4% · Average volume (30d) 133.6K

Analysts

Price target, next 12 months$5.00+327.4%Median of 7 analysts · vs the Aug 28 close

ConsensusBuy4 of 7 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.17

High$175.00+14,857.3%

Median$5.00+327.4%

Low$1.00−14.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Target
May 20, 2025	Maxim Group	Upgrade	Hold	Buy	$8
Nov 15, 2024	Ladenburg Thalmann	Downgrade	Buy	Neutral

Earnings

EPS

Estimate−$0.45

ReportedDue Nov 12, 2026

Revenue

Estimate$8.4M

ReportedDue Nov 12, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.67	−$0.64	+4.5%	$7.6M	$8.2M	+8.2%	+2.59%
May 13, 2026Q1 FY26	−$0.81	−$0.76	+6.2%	$6.6M	$6.7M	+1.8%	−4.80%
Mar 23, 2026Q4 FY25	−$0.81	−$0.03	+96.3%	$7.9M	$8.0M	+0.9%	−19.18%
Nov 13, 2025Q3 FY25	−$1.81	−$1.59	+12.2%	$7.9M	$7.4M	−6.7%	+3.40%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$6.5M	$6.7M	$7.4M	$8.0M	$6.7M	$8.2M
Gross profit	$2.9M	$3.5M	$3.4M	$3.4M	$3.3M	$4.3M
Operating income	−$8.5M	−$7.8M	−$8.5M	−$8.5M	−$7.9M	−$7.2M
Net income	−$3.1M	−$6.9M	−$8.5M	−$7.9M	−$8.3M	−$7.4M
Diluted EPS	−$1.15	−$1.99	−$1.59	−$0.74	−$0.76	−$0.64
Gross margin	45.5%	51.6%	45.7%	42.7%	48.6%	52.8%
Operating margin	-131.1%	-115.8%	-115.9%	-107.4%	-118.1%	-88.3%

Fiscal years (4-quarter sums)FY21 $18.0M · FY22 $27.8M · FY23 $36.1M · FY24 $30.8M · FY25 $28.5M

Revenue by product · Q2 FY26

Product$7.7M · 48%

Consumable Revenue$4.3M · 27%

Instrument Revenue$2.0M · 13%

Software Revenue$1.4M · 9%

Product And Service, Other$478.0K · 3%

Revenue by geography · Q2 FY26

EMEA$4.8M · 59%

Americas$3.0M · 37%

Asia Pacific$307.0K · 4%

Balance sheet, Jun 30, 2026Cash & short-term investments $9.9M · Total debt $6.7M · Total assets $47.6M · Shareholders' equity $31.6M

Dividends

No dividends on record.

Ownership

Institutions 7.59%870.7K sharesInsiders 0.07%7.7K sharesOther 92.34%10.60M shares

Shares outstanding 11.48M · Float 10.78M · 94.0% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
CVI Investments, Inc.	1.13M	9.90%	13G	Feb 17, 2026
Lind Global Fund III LP	1.05M	9.35%	13G	Feb 17, 2026
Ayrton Capital LLC	528.2K	9.99%	13G	Nov 13, 2025
Lincoln Alternative Strategies LLC	525.0K	5.42%	13G	Sep 17, 2025
Gsa Capital Partners LLP	353.4K	3.08%	13F	May 8, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 21, 2026	Albert Luderer	director, officer: Interim Chief Executive	+4,000	$1.22